EGAPP|Evaluation of Genomic Applications in Practice and Prevention|Home

EGAPP|Evaluation of Genomic Applications in Practice and Prevention|Home

he EGAPP Working Group was established in 2005 to support the development of a systematic process for assessing the available evidence regarding the validity and utility of rapidly emerging genetic tests for clinical practice.  This independent, multidisciplinary panel prioritizes and selects tests, reviews CDC-commissioned evidence reports and other contextual factors, highlights critical knowledge gaps, and provides guidance on appropriate use of genetic tests in specific clinical scenarios.
 
Nominations for EGAPP Working Group membership are accepted on a continuous basis.

EGAPP Recommendations

Cardiovascular Health: Outcomes of Genetic Testing in Adults with a History of Venous Thromboembolism Breast Cancer: Can tumor gene expression profiling   improve outcomes… Cardiovascular Health: Genomic profiling to assess cardiovascular risk to improve cardiovascular health… Colorectal Cancer (Lynch syndrome): Genetic testing strategies in newly diagnosed individuals… Colorectal Cancer: Can UGT1A1 genotyping reduce morbidity and mortality… Depression: Testing for cytochrome P450 polymorphisms in adults…    What's New The next EWG meeting is being held on May 7and 8, 2012. Two new members of the EGAPP Working Group, with experience and expertise in pharmacogenomics and public health, will be selected in 2012. Nominate yourself or someone you know today! The last EWG meeting was held on January 30 and 31, 2012. more